Vanguard Investments Australia’s Corvus Pharmaceuticals CRVS Stock Holding History

Vanguard Investments Australia’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	+16,192	New	+$225K	﹤0.01%	2029

Other funds holding CRVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Investments Australia's CRVS Position: Q2 2026 in Review

Vanguard Investments Australia opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 16,192 shares worth $242K. The stake represents ﹤0.01% of the portfolio and ranks #2029 among its holdings.

160 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Vanguard Investments Australia held 16,192 shares of Corvus Pharmaceuticals worth $242K as of Q2 2026.
Corvus Pharmaceuticals was a new Vanguard Investments Australia position in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2029 holding.
160 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.